1. Home
  2. COHR vs ARGX Comparison

COHR vs ARGX Comparison

Compare COHR & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Coherent Corp.

COHR

Coherent Corp.

HOLD

Current Price

$335.51

Market Cap

53.1B

Sector

Technology

ML Signal

HOLD

Logo argenx SE

ARGX

argenx SE

HOLD

Current Price

$872.58

Market Cap

58.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
COHR
ARGX
Founded
1971
2008
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Electronic Components
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
53.1B
58.4B
IPO Year
1995
2017

Fundamental Metrics

Financial Performance
Metric
COHR
ARGX
Price
$335.51
$872.58
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
14
19
Target Price
$264.62
$1,008.56
AVG Volume (30 Days)
4.2M
273.5K
Earning Date
05-06-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
71.74
N/A
EPS
2.92
N/A
Revenue
$1,158,794,000.00
N/A
Revenue This Year
$21.72
$44.39
Revenue Next Year
$24.63
$20.84
P/E Ratio
$112.41
$33.69
Revenue Growth
19.21
N/A
52 Week Low
$84.35
$631.74
52 Week High
$440.00
$953.58

Technical Indicators

Market Signals
Indicator
COHR
ARGX
Relative Strength Index (RSI) 50.78 52.25
Support Level $297.53 $822.56
Resistance Level $327.78 $938.44
Average True Range (ATR) 22.12 25.40
MACD 7.83 -1.90
Stochastic Oscillator 70.34 52.18

Price Performance

Historical Comparison
COHR
ARGX

About COHR Coherent Corp.

Coherent Corp is a vertically integrated manufacturing company that develops, manufactures, and markets lasers, transceivers, and other optical and optoelectronic devices, modules, and systems, as well as engineered materials, for use in the communications, industrial, instrumentation, and electronics markets. Its reporting segments are Datacenter Communications and Industrial. Its geographic areas are North America, Europe, China, Japan, and the rest of the world.

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Share on Social Networks: